Uterine papillary serous cancer: A review of the literature

Gynecologic Oncology

Volumn 127, Issue 3, 2012, Pages 651-661

  Del Carmen, Marcela G ^a   Birrer, Michael ^a   Schorge, John O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Radiation; Surgery; Uterine serous cancer

Indexed keywords

PLATINUM; TAXANE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; ENDOMETRIUM CANCER; HISTOPATHOLOGY; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOGENESIS; PRIORITY JOURNAL; RARE DISEASE; REVIEW; UTERINE PAPILLARY SEROUS CANCER; UTERUS CANCER;

CA-125 ANTIGEN; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; NEOPLASM STAGING; UTERINE NEOPLASMS;

EID: 84868540623     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.09.012     Document Type: Review

References (146)

1. R. Siegel, E. Ward, O. Brawley, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. C.L. Creutzberg, W.L. van Putten, P.C. Koper, M.L. Lybeert, J.J. Jobsen, and C.C. Warlam-Rodenhuis Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma Lancet 355 2000 1404 1411
3. M. Hendrickson, J. Ross, P. Eifel, A. Martinez, and R. Kempson Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma Am J Surg Pathol 6 1982 93 108
4. B.M. Slomovitz, T.W. Burke, P.J. Eifel, L.M. Ramondetta, E.G. Silva, and A. Jhingran Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases Gynecol Oncol 91 2003 463 469
5. J.L. Nicklin, and L.J. Copeland Endometrial papillary serous carcinoma: patterns of spread and treatment Clin Obstet Gynecol 39 1996 686 695
6. C. Trope, G.B. Kristensen, and V.M. Abeler Clear-cell and papillary serous cancer: treatment options Best Pract Res Clin Obstet Gynaecol 15 2001 433 446
7. R.P. Matthews, J. Hutchinson-Colas, M. Maiman, R.G. Fruchter, E.J. Gates, and D. Gibbon Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women Gynecol Oncol 65 1997 206 212
8. R.W. Naumann Uterine papillary serous carcinoma: state of the state Curr Oncol Rep 10 2008 505 511
9. R.E. Bristow, F. Asrari, E.L. Trimble, and F.J. Montz Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease Gynecol Oncol 81 2001 279 286
10. S.C. Lauchlan Tubal (serous) carcinoma of the endometrium Arch Pathol Lab Med 105 1981 615 618
11. M. Hendrickson, J. Ross, P. Eifel, A. Martinez, and R. Kempson Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma Am J Surg Pathol 6 1982 93 108
12. J.V. Bokhman Two pathogenic types of endometrial carcinoma Gynecol Oncol 15 1983 10 17
13. M.L. McCullough, A.V. Patel, R. Patel, C. Rodriguez, H.S. Feigelson, and E.V. Bandera Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype Cancer Epidemiol Biomarkers Prev 17 2008 73 79
14. T. Bjorge, A. Engeland, S. Tretli, and E. Weiderpass Body size in relation to cancer of the uterine corpus in 1 million Norwegian women Int J Cancer 120 2007 378 383
15. J.A. Lachance, E.N. Everett, B. Greer, L. Mandel, E. Swisher, and H. Tamimi The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer Gynecol Oncol 101 2006 470 475
16. R.A. Soslow, J.P. Bissonnette, A. Wilton, S.E. Ferguson, K.M. Alektiar, and L.R. Duska Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences Am J Surg Pathol 31 2007 979 987
17. W.T. Creasman, M.F. Kohler, F. Odicino, P. Maisonneuve, and P. Boyle Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium Gynecol Oncol 95 2004 593 596
18. C.A. Hamilton, M.K. Cheung, K. Osann, L. Chen, N.N. Teng, and T.A. Longracre Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers Br J Cancer 94 2006 642 646
19. C.J. Dunton, G. Balsara, M. McFarland, and E. Hernandez Uterine papillary serous carcinoma: a review Obstet Gynecol Surv 46 1991 97 102
20. B.M. Slomovitz, T.M. Burke, P.J. Eifel, L.M. Ramodetta, E.G. Silva, and A. Jhingran Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases Gynecol Oncol 91 2003 463 469
21. D.M. Boruta, P.A. Gehrig, A. Nickles Fader, and A. Olawaiye Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review Gynecol Oncol 115 2009 142 153
22. D.M. Boruta 2nd, P.A. Gehrig, P.A. Groben, V. Bae-Jump, J.F. Boggess, and W.C. Fowler Jr. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 101 2004 2214 2221
23. J. Farley, J.L. Risinger, G.S. Rose, and G.L. Maxwell Racial disparities in blacks with gynecologic cancers Cancer 110 2007 234 243
24. G.L. Maxwell, C. Tian, J. Risinger, C.L. Brown, G.S. Rose, and J.T. Thigpen Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study Cancer 107 2006 2197 2205
25. M.E. Sherman, and S.S. Devesa Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus Cancer 98 2003 176 186
26. W.B. Growdon, A.J. Rauh-Hain, A. Cordon, L.A. Garrett, J.O. Schorge, and A.K. Goodman Prognostic determinants in patients with stage I uterine papillary serous carcinoma. A 15-year multi-institutional review Int J Gyencol Oncol 22 2012 417 424
27. P.A. Gehrig, V.L. Bae-Jump, J.F. Boggess, P.A. Groben, W.C. Fowler Jr., and L. Van Le Association between uterine serous carcinoma and breast cancer Gynecol Oncol 94 2004 208 211
28. J.K. Chan, M.R. Manuel, M.K. Cheung, K. Osann, A. Husain, and N.N. Teng Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Gynecol Oncol 102 2006 508 512
29. J.P. Geisler, J.L. Sorosky, H.L. Duong, T.E. Buekers, M.J. Geisler, and A.K. Sood Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma Gynecol Oncol 83 2001 501 503
30. J.A. Rauh-Hain, W.B. Growdon, J.O. Schorge, A.K. Goodman, D.M. Boruta, and C. McCann Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma Gynecol Oncol 2010 299 304
31. J.K. Chan, V. Loizzi, M. Youssef, K. Osann, K. Rutgers, and S.A. Vasilev Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium Gynecol Oncol 90 2003 181 185
32. B. Fisher, J.P. Costantino, D.L. Wickerham, R.S. Cecchini, W.M. Cronin, and A. Robidoux Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J Natl Cancer Inst 97 2005 1652 1662
33. R.R. Barakat, G. Wong, J.P. Curtin, V. Vlamis, and W.J. Hoskins Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features Gynecol Oncol 55 1994 164 168
34. L. Bergman, M.L. Beelen, M.P. Gallee, H. Hollema, J. Benraadt, and F.E. van Leeuwen Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centers' ALERT Group. Assessment of live and endometrial cancer risk following tamoxifen Lancet 356 2000 881 887
35. U. Magriples, F. Naftolin, P.E. Schwartz, and M.L. Carcangiu High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients J Clin Oncol 11 1993 485 490
36. R. Goshen, W. Chu, L. Elit, T. Pal, J. Hakimi, and I. Ackerman Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol 79 2000 477 481
37. O. Lavie, G. Hornreich, A. Ben-Arie, P. Renbaum, E. Levy-Lahad, and U. Beller BRCA1 germline mutations in women with uterine papillary serous carcinoma Obstet Gynecol 96 2000 28 32
38. O. Lavie, G. Hornreich, A. Ben-Arie, G. Rennert, Y. Cohen, and R. Keidar BRCA germline mutations in Jewish women with uterine serous papillary carcinoma Obstet Gynecol 92 2004 521 524
39. D.A. Levine, Lin, R.R. Barakat, M.E. Robson, D. McDermott, and L. Cohen Risk of endometrial carcinoma associated with BRCA mutation Gynecol Oncol 80 2001 395 398
40. J.P. Geisler Patients having prophylactic surgery for family history or known genetic mutations: why save the uterus? Gynecol Oncol 104 2007 780 781
41. J.L. Hecht, and G.L. Mutter Molecular and pathologic aspects of endometrial carcinogenesis J Clin Oncol 24 2006 4783 4791
42. W. Zheng, P. Cao, M. Zheng, E.E. Kramer, and T.A. Godwin P53 overexpression and bcl-2 persistence in endometrial carcinoma: a comparison of papillary serous and endometrioid subtypes Gynecol Oncol 61 1996 167 174
43. A.D. Santin, S. Bellone, M. Gokden, M. Palmieri, D. Dunn, and J. Agha Overexpression of HER-2/neu in uterine serous papillary cancer Clin Cancer Res 8 2002 1271 1279
44. P. Singh, C.L. Smith, G. Cheetham, T.J. Dodd, and M.L. Davy Serous carcinoma of the uterus-determination of HER-2/neu status immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation Int J Gynecol Cancer 18 2008 1344 1351
45. E. Kuhn, R.C. Wu, B. Guan, G. Wu, J. Zhang, and Y. Wang Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses JNCI Aug 23 2012 [Electronic publication ahead of print]
46. J.A. Villella, S. Coher, D.H. Smith, H. Hibshoosh, and D. Hershman Her-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications Int J Gynecol Cancer 16 2006 1897 1902
47. A.D. Santin, S. Bellone, S. Van Stedum, W. Bushen, M. Palmieri, and E.R. Siegel Amplification of c-erbB2 oncogene: a major prognostic indicator of uterine serous papillary carcinoma Cancer 104 2005 1391 1397
48. F.E. Odicino, E. Bignoti, E. Rossi, B. Pasinetti, R.A. Tassi, and C. Donzelli HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction and fluorescence in situ hybridization Int J Gynecol Cancer 18 2008 14 21
49. L. Bradford, J. Zhang, D. Groeneweg, J. Borger, R. Engelman, and R. Foster Inhibition of PI3K-AKT signaling precludes endometrial cancer growth in a primary xenograft model harboring an oncogenic PIK3CA mutation Gynecol Oncol 125 2012 S128 S129 [abstract]
50. D. Iglesias, J. Burzawa, Q. Zhang, J. Co, M. Celestino, and M. Yates Pre-clinical in vitro and in vivo evidence to support personalized biologic treatment of endometrial cancer with metformin and PI3K pathway inhibitors Gynecol Oncol 125 2012 S136 [abstract]
51. C. Lai, A. Lin, S. Chao, T. Hsueh, and T. Wang Lapatinib induces downregulation of matrix metallopeptidase 1 and deactivation of ERK1/2 and PIK3 pathway in endometrial cancer Gynecol Oncol 125 2012 S173 [abstract]
52. R.A. Ambros, M.E. Sherman, C.M. Zahn, R. Bitterman, and R.J. Kurman Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation Hum Pathol 26 1995 1260 1267
53. M.E. Sherman, P. Bitterman, N.B. Rosenshein, G. Delgado, and R.J. Kurman Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features Am J Surg Pathol 16 1992 600 610
54. M.L. Carcangiu, L.K. Tan, and J.T. Chambers Stage IA uterine serous carcinoma: a study of 13 cases Am J Surg Pathol 21 1997 1507 1514
55. P.A. Gehrig, P.A. Groben, W.C. Fowler Jr., L.A. Walton, and L. Van Le Noninvasive papillary serous carcinoma of the endometrium Obstet Gynecol 97 2001 153 157
56. B.A. Goff, D. Kato, R.K. Schmidt, M. Ek, J.A. Ferry, and H.C. Muntz Uterine papillary serous carcinoma: patterns of metastatic spread Gynecol Oncol 54 1994 264 268
57. E.G. Silva, and R. Jenkins Serous carcinoma in endometrial polyps Mod Pathol 3 1990 120 128
58. D.T. Wheeler, K.A. Bell, R.J. Kurman, and M.E. Sherman Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation Am J Surg Pathol 24 2000 797 806
59. K.R. Lee, and J.L. Belinson Recurrence of noninvasive endometrial carcinoma. Relationship to uterine papillary serous carcinoma Am J Surg Pathol 15 1991 965 973
60. W. Zheng, and P.E. Schwartz Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical manifestations Gynecol Oncol 96 2005 579 582
61. X. Yi, and W. Zheng Endometrial glandular dysplasia and endometrial intraepithelial neoplasia Curr Opin Obstet Gynecol 20 2008 20 25
62. W. Zheng, S.X. Liang, X. Yi, E.C. Ulukus, J.R. Davis, and S.K. Chambers Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma Int J Gyencol Pathol 26 2007 38 52
63. W. Zheng, S.X. Liang, H. Yu, T. Rutherford, S.K. Chambers, and P.E. Schwartz Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma, Part I: morphologic features Int J Surg Pathol 12 2004 207 223
64. G.S. Huang, J.S. Gebb, M.H. Einstein, S. Shahabi, A.P. Novetsky, and G.L. Goldberg Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors Am J Obstet Gynecol 196 2007 243.e1 243.e5
65. J. Wang, C. Wieslander, G. Hansen, I. Cass, S. Vasilev, and C.H. Holschneider Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers Gynecol Oncol 101 2006 120 125
66. O. Grigoriiu, A. Kalovidouros, C. Papadias, G. Antoniou, V. Antonaki, and L. Giannikos Transvaginal sonography of the endometrium in women with postmenopausal bleeding Maturitas 23 1996 9 14
67. M. Signorelli, L. Guerra, A. Buda, M. Picchio, G. Mangili, and T. Dell'Anna Role of the integrated PDG PET/CT in the surgical management of patients with high risk clinical stage endometrial cancer: detection of pelvic nodal metastases Gynecol Oncol 115 2009 231 235
68. M. Picchio, G. Mangili, A.M. Samanes Gajate, P. De Marzi, E.G. Spinapolice, and P. Mapelli High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging Nucl Med Commun 31 2010 506 512
69. I. Ak, M.P. Stokkel, and E.K. Pauwels Positron emission tomography with 2-[18F] fluoro-2-deoxy-d glucose in oncology. Part II. The clinical value in detecting and staging primary tumours J Cancer Res Clin Oncol 12 2000 560 574
70. A. Chao, T.C. Chang, and K.K. Ng 18F-FDG PET in the management of endometrial cancer Eur J Nucl Med Mol Imaging 33 2006 36 44
71. R. Suzuki, E. Miyagi, and N. Takahashi Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer Int J Gynecol Cancer 17 2007 890 896
72. N.S. Horowitz, F. Dehdashti, and T.J. Herzog Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer Gynecol Oncol 95 2004 546 551
73. J.M. Niloff, T.L. Klug, E. Schaetzl, V.R. Zurawski, R.C. Knapp, and R.C. Bast Evaluation of serum CA-125 in carcinomas of the fallopian tube, endometrium, and endocervix Am J Obstet Gynecol 148 1984 1057 1058
74. A.B. Olawaiye, J.A. Rauh-Hain, M. Withiam-Leitch, B. Rueda, A.K. Goodman, and M.G. del Carmen Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma Gynecol Oncol 110 2008 293 298
75. J.M. Duk, J.G. Aalder, G.J. Fleuren, and H.W. de Brujin CA 125: a useful marker in endometrial carcinoma Am J Obstet Gynecol 155 1986 1097 1102
76. M. Patsner, W.J. Mann, H. Cohen, and M. Loesch Predictive or preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma Am J Obstet Gynecol 158 1988 399 402
77. A.K. Sood, R.E. Buller, R.A. Burger, J.D. Dawson, J.I. Sorosky, and M. Berman Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome Obstet Gynecol 90 1997 441 447
78. K.A. Moller, P.A. Gehrig, L. Van Le, A.A. Secord, and J.O.S. Schorge The role of optimal debulking in advanced stage serous carcinoma of the uterus Gynecol Oncol 94 2004 170 174
79. R.G. Moore, A.K. Brown, M.C. Miller, D. Badgewell, Z. Lu, and W.J. Allard Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus Gynecol Oncol 110 2008 196 201
80. Z. Yurkovetsky, S. Ta'asan, S. Skates, A. Rand, A. Lomakin, and F. Linkov Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin Gynecol Oncol 107 2007 58 65
81. C.S. Diefenbach, Z. Shah, A. Iasonos, R.R. Barakat, D.A. Levine, and C. Aghajanian Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer Gynecol Oncol 104 2007 435 442
82. E. Despierre, P. Moerman, I. Vergote, and F. Amant Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma? Int J Gynecol Cancer 16 2006 273 277
83. T.D. Le, S.D. Yamada, J.L. Rutgers, and P.J. DiSaia Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin Gynecol Oncol 73 1999 461 463
84. P.V. Price, R.M. Amin, and J. Sumkin Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma Gynecol Oncol 73 1999 140 144
85. E. Resnik, and J.B. Taxy Neoadjuvant chemotherapy in uterine papillary serous carcinoma Gynecol Oncol 62 1996 123 127
86. J.K. Chan, M.K. Cheung, W.K. Huh, K. Osann, A. Husain, and N.N. Teng Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients Cancer 107 2006 1823 1830
87. H. Kitchener, A.M. Swart, Q. Qian, C. Amos, and M.K. Parmar Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study Lancet 373 2009 125 136
88. FIGO Committee on Gynecologic Oncology The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas Gynecol Oncol 115 2009 325 328
89. J.P. Geisler, H.E. Geisler, M.E. Melton, and M.C. Wiemann What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol 74 1999 465 467
90. P.A. Gehrig, L. Van LE, and W.C. Fowler Jr. The role of omentectomy during the surgical stating of uterine serous carcinoma Int J Gynecol Cancer 13 2003 212 215
91. M.L. Carcangiu, and J.T. Chambers Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma Gynecol Oncol 47 1992 298 305
92. P. Hui, M. Kelly, D.M. O'Malley, F. Tavassolli, and P.E. Schwartz Minimal uterine serous carcinoma: a clinicopathological study of 40 cases Mod Pathol 18 2005 75 82
93. B.C. Turner, J.P. Knisely, B.M. Kacinsky, B.G. Haffty, A.A. Gumbs, and K.B. Roberts Effective treatment of stage I uterine papillary serous carcinoma of the endometrium Gynecol Oncol 90 2003 181 185
94. A.N. Fader, D. Starks, P.G. Rose, E. Tuller, H. Gibbons, and F. Abushanin Percentage UPSC, lymphovascular invasion, and tumor size are not independent predictors of recurrence Gynecol Oncol 112 2009 S72 S74
95. R.E. Bristow, L.R. Duska, and F.J. Montz The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma Gynecol Oncol 81 2001 92 99
96. R.E. Bristow, M.J. Zerbe, N.B. Rosenshein, F.C. Grumbine, and F.J. Montz Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival Gynecol Oncol 78 2000 85 91
97. D.S. Chi, M. Welshinger, E.S. Venkatraman, and R.R. Barakat The role of surgical cytoreduction in Stage IV endometrial carcinoma Gynecol Oncol 67 1997 56 60
98. N.C. Lambrou, O. Gomez-Marin, R. Mirhashemi, H. Beach, E. Salom, and Z. Almeida-Parra Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival Gynecol Oncol 93 2004 653 658
99. S. Memarzadeh, C.H. Holschneider, R.E. Bristow, N.L. Jones, Y.S. Fu, and B.Y. Karlan FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival Int J Gynecol Cancer 12 2002 454 458
100. M.B. Thomas, A. Mariani, W.A. Cliby, G.L. Keeney, K.C. Podratz, and S.C. Dowdy Role of cytoreduction in stage III and IV uterine papillary serous carcinoma Gynecol Oncol 107 2007 190 193
101. C.P. Morrow, B.N. Bundy, R.J. Kurman, W.T. Creasman, P. Heller, and H.D. Homesley Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study Gynecol Oncol 40 1991 55 65
102. B.M. Sood, J. Jones, S. Gupta, D. Khabele, C. Guha, and C. Runowicz Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma Int J Radiat Oncol Biol Phys 57 2003 208 216
103. C.S. Dietrich III, S.C. Modesitt, P.D. DePriest, F.R. Ueland, J. Wilder, and M.B. Reedy The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC) Gynecol Oncol 99 2005 557 563
104. A.N. Fader, R.D. Drake, D.M. O'Malley, H.E. Gibbons, W.K. Huh, and L.J. Havrilesky Platinum/taxane-based chemotherapy with or without radiotherapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma Cancer 115 2009 2119 2127
105. M.G. Kelly, D.M. O'Malley, P. Hui, J. McAlpine, H. Yu, and T.J. Rutherford Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy Gynecol Oncol 98 2005 353 359
106. M.B. Thomas, A. Mariani, W.A. Cliby, G.A. Keeney, K.C. Podratz, and S.C. Dowdy Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma Gynecol Oncol 107 2007 186 189
107. L.J. Havrilesky, A.A. Secord, V. Bae-Jump, T. Ayeni, B. Calingaert, and D.L. Clarke-Pearson Outcomes in surgical stage I uterine papillary serous carcinoma Gynecol Oncol 105 2007 677 682
108. L. Elit, J. Kwon, J. Bentley, K. Trim, I. Ackerman, and M. Carey Optimal management for surgically Stage 1 serous cancer of the uterus Gynecol Oncol 92 2004 240 246
109. W.K. Huh, M. Powell, C.A. Leath III, J.M. Straughn Jr., D.E. Cohn, and M.A. Gold Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy Gynecol Oncol 91 2003 470 475
110. A.N. Fader, C. Nagel, A.E. Axtell, K.M. Zanotti, J.P. Kelley, and K.N. Moore Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improve recurrence and survival outcomes Gynecol Oncol 112 2009 558 562
111. P.J. Hoskins, K.D. Swenerton, J.A. Pike, F. Wong, P. Lim, and C. Acquino-Parsons Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study J Clin Oncol 19 2001 4048 4053
112. D. Pectasides, N. Xiros, G. Papaxoinis, E. Pectasides, C. Sykiotis, and A. Koumarianou Carboplatin and paclitaxel in advanced or metastatic endometrial cancer Gynecol Oncol 109 2008 250 254
113. T. Akram, P. Maseelall, and J. Fanning Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer Am J Obstet Gynecol 192 2005 1365 1369
114. M.A. Sovak, M.L. Hensley, J. Dupont, N. Ishill, K.M. Alektiar, and N. Abu-Rustum Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study Gynecol Oncol 103 2 2006 451 457
115. B. Sorbe, H. Anderson, and K. Boman Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up Int J Gynecol Cancer 18 2008 803 807
116. L. Ramondetta, T.W. Burke, C. Levenback, M. Bevers, D. Bodurka-Bevers, and D.M. Gershenson Treatment of uterine papillary serous carcinoma with paclitaxel Gynecol Oncol 82 1 2001 Jul 156 161
117. K.M. Zanotti, J.L. Belinson, A.W. Kennedy, K.D. Webster, and M. Markman The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma Gynecol Oncol 74 1999 272 277
118. T.D. Le, S.D. Yamada, J.L. Rutgers, and P.J. DiSaia Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with taxol and carboplatin Gynecol Oncol 73 1999 461 465
119. G.H. Eltabbakh, J. Moody, L.L. Garafano, and J.M. Hammond The combination paclitaxel, carboplatin and megestrol acetate is effective in women with recurrent uterine papillary serous adenocarcinoma Eur J Gynaecol Oncol 20 1999 18 21
120. A.P. Vaidya, R. Littell, C. Krasner, and L.R. Duska Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel Int J Gynecol Cancer 16 2006 267 272
121. H.D. Homesley, V. Filiaci, S.K. Gibbons, H.J. Long, D. Cella, and N.M. Spirtos A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study Gynecol Oncol 22 2008 131 136
122. G.F. Fleming, V.L. Brunetto, D. Cella, K.Y. Look, G.C. Reid, and A.R. Munkarah Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 22 2004 2159 2166
123. D.S. McMeekin, V.L. Filiaci, J.T. Thigpen, H.H. Gallion, G.F. Fleming, and W.H. Rodgers The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study Gynecol Oncol 106 2007 16 22
124. D.S. Miller Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study http://www.sgomeetingsonwomenscancer.com/#!media/vstc9= media-resources [Accessed May 11, 2012]
125. J. Kwon, I. Ackerman, and E. Franssen The role of abdominal-pelvic radiotherapy in the management of uterine papillary serous carcinoma Int J Radiat Oncol Biol Phys 59 2004 1439 1445
126. P. Lim, A. Al Kushi, B. Gilks, F. Wong, and C. Aquino-Parsons Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome Cancer 91 2001 752 757
127. A.A. Martinez, S. Weiner, K. Podratz, A.R. Armin, J.S. Stromberg, and R. Stanhope Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdominopelvic irradiation Gynecol Oncol 90 2003 537 546
128. N. Mehta, S.D. Yamada, J. Rotmensch, and A.J. Mundt Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy Int J Radiat Oncol Biol Phys 57 2003 1004 1009
129. G. Sutton, J.H. Axelrod, B.N. Bundy, T. Roy, H. Homesley, and R.B. Lee Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group Gynecol Oncol 100 2006 349 354
130. K. Greven, K. Winter, K. Underhill, J. Fontenesci, J. Cooper, and T. Burke Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer Gynecol Oncol 103 2006 155 159
131. T. Hogberg, P. Rosenberg, G. Kristensen, C.F. de Oliveira, R. de Pont Christensen, B. Sorbe, and C. Lundgren A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) J Clin Oncol 25 2007 5503
132. N. Susumu, S. Sagae, Y. Udagawa, K. Niwa, H. Kuramoto, and S. Satoh Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study Gynecol Oncol 108 2008 226 233
133. G. Sutton, J.H. Axelrod, B.N. Bundy, T. Roy, H.D. Homesley, and J.H. Malfetano Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study Gynecol Oncol 97 2005 755 763
134. P.A. Gehrig, D.E. Morris, and L. Van Le Uterine serous carcinoma: a comparison of therapy for advanced-stage disease Int J Gynecol Cancer 14 2004 515 520
135. C.A. Hamilton, M.K. Cheung, K. Osann, B. Balzer, M.L. Berman, and A. Husain The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma Gynecol Oncol 103 2006 679 683
136. H. Steed, L. Manchul, B. Rosen, A. Fyles, G. Lockwood, and S. Laframboise Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy Int J Gynecol Cancer 16 2006 278 285
137. G. Gitsch, M.L. Friedlander, G.V. Wain, and N.F. Hacker Uterine papillary serous carcinoma. A clinical study Cancer 75 1995 2239 2243
138. H. Goldberg, R.C. Miller, R. Abdah-Bortnyak, M. Steiner, F. Yildiz, and A. Meirovitz Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN) Gynecol Oncol 108 2008 298 305
139. M.E. Randall, V.L. Filiaci, H. Muss, N.M. Spirtos, R.S. Mannel, and J. Fowler Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 24 2006 36 44
140. J.S. Low, E.H. Wong, H.S. Tan, S.P. Yap, E.J. Chua, and V.K. Sethi Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma Gynecol Oncol 97 2005 171 177
141. L.R. Duska, R. Berkowitz, U. Matulonis, M. Muto, A. Goodman, and J.F. McIntyre A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with high-risk endometrial cancer Gynecol Oncol 96 2005 198 203
142. A.L. Fields, M.H. Einstein, A.P. Novetsky, J. Gebb, and G.L. Goldberg Pilot phase II trial of radiation sandwiched between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC) Gynecol Oncol 108 2008 201 206
143. A.A. Secord, L.J. Havrilesky, O. Malley DM, V. Bae-Jump, N.D. Fleming, and G. Broadwater A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer Gynecol Oncol 112 2009 S12 S15
144. G.F. Fleming, M.W. Sill, K.M. Darcy, D.S. McMeekin, J.T. Thigpen, and L.M. Adler Phase II, trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 116 2010 15 20
145. A.D. Santin Letter to the Editor referring to the manuscript entitled: Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study recently reported by Fleming et al. Gynecol Oncol 118 2010 95 96
146. M. Ruiz Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2 + metastatic breast cancer Cancer Chemother Pharmacol 62 2008 1085 1090